Predict your next investment

trans-science.co.uk

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Funds

5

About Trans-Science

Trans-Science Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Trans-Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Trans-Science in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Trans-Science Investments

2 Investments

Trans-Science has made 2 investments. Their latest investment was in Acucela as part of their Series B on November 11, 2004.

CBI Logo

Trans-Science Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/15/2004

Series B

Acucela

$13.4M

Yes

10/19/2004

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/15/2004

10/19/2004

Round

Series B

Series B

Company

Acucela

Subscribe to see more

Amount

$13.4M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

10

Trans-Science Portfolio Exits

1 Portfolio Exit

Trans-Science has 1 portfolio exit. Their latest portfolio exit was Acuity Pharmaceuticals on March 28, 2007.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/28/2007

Reverse Merger

1

Date

3/28/2007

Exit

Reverse Merger

Companies

Valuation

Acquirer

Sources

1

Trans-Science Fund History

5 Fund Histories

Trans-Science has 5 funds, including Trans-Science Bio Contents Limited Partnership.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/26/2006

Trans-Science Bio Contents Limited Partnership

Multi-Stage Venture Capital

1

6/21/2006

Trans-Science Material Investment Limited Partners

Subscribe to see more

$99M

10

12/14/2004

Trans-Science No.3 Investments Limited Partnership

Subscribe to see more

$99M

10

3/9/2004

Trans-Science No.2 Investments Limited Partnership

Subscribe to see more

$99M

10

6/20/2002

Trans-Science No.1 Investments Limited Partnership

Subscribe to see more

$99M

10

Closing Date

12/26/2006

6/21/2006

12/14/2004

3/9/2004

6/20/2002

Fund

Trans-Science Bio Contents Limited Partnership

Trans-Science Material Investment Limited Partners

Trans-Science No.3 Investments Limited Partnership

Trans-Science No.2 Investments Limited Partnership

Trans-Science No.1 Investments Limited Partnership

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Trans-Science Team

5 Team Members

Trans-Science has 5 team members, including current Chief Executive Officer, President, Kiyoshi Inoue.

Name

Work History

Title

Status

Kiyoshi Inoue

Chief Executive Officer, President

Current

Hideki Numabe

Chief Financial Officer

Current

Hideki Terauchi

Chief Financial Officer

Current

Ryuji Kuwana

Chief Operating Officer

Current

Naoji Sato

Chief Operating Officer

Current

Name

Kiyoshi Inoue

Hideki Numabe

Hideki Terauchi

Ryuji Kuwana

Naoji Sato

Work History

Title

Chief Executive Officer, President

Chief Financial Officer

Chief Financial Officer

Chief Operating Officer

Chief Operating Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.